Lansdowne Partners, the London investment manager pivoting into venture capital, announced a €128.9m first close on 14 May for a new fund targeting UK university IP spinouts, with the British Business Bank (BBB) as anchor LP alongside Aviva Investors and Lloyds Banking Group 1. The fund's named target sectors are healthcare data, quantum, advanced materials, semiconductors and defence; final close in December 2026 targets €171.9m. Lansdowne's prior track-record cites Oxford Nanopore, Raspberry Pi, Oxford Ionics and Helsing.
The BBB's anchor LP commitment uses the £6.6bn expanded mandate the bank received in April , but at fund-of-funds tempo rather than direct-cheque tempo. The bank's headline direct cheques in May went into Quantum Motion , Cytospire Therapeutics and Elliptic , all £12m to £40m equity tickets into companies already at Series A or later. Lansdowne's vehicle reaches further down the ladder, into the spinout formation band that the 30% to 20% VCT relief cut and the EMI gross-asset reforms widened.
Semiconductors and quantum sit on the target list together. That overlap with CamGraPhIC's Italian-state-aid award is the more telling pairing. Lansdowne is reaching for the kind of physical photonics and quantum hardware companies Brussels was willing to write a €211m factory cheque for; the LP base is testing whether a smaller, equity-only UK answer can keep that IP onshore once a spinout reaches Series B. The structural counter-reading is that fund-of-funds investing is BBB hedging by another name: cornerstone an LP slot in a private GP rather than pick winners under public eligibility criteria.
